Collegium Pharmaceutical, Inc. Sustainability Profile
Collegium Pharmaceutical, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has made significant strides in developing innovative pain management solutions, particularly focusing on abuse-deterrent formulations. With a commitment to addressing the opioid crisis, Collegium has positioned itself as a pioneer in creating safer alternatives for patients. The company’s flagship product, Xtampza ER, is an extended-release formulation of oxycodone designed to reduce the potential for misuse. Collegium's unique approach to pain management, combined with its robust pipeline of products, underscores its dedication to improving patient outcomes. With a strong market presence and a focus on responsible prescribing, Collegium Pharmaceutical continues to achieve notable milestones in the evolving landscape of pain management therapies.
DitchCarbon Score
How does Collegium Pharmaceutical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Collegium Pharmaceutical, Inc.'s score of 25 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Collegium Pharmaceutical, Inc.'s reported carbon emissions
Collegium Pharmaceutical, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The absence of emissions data suggests that the company may not have established formal climate commitments or reduction strategies at this time. As a result, there are no specific figures to report regarding their Scope 1, 2, or 3 emissions. Additionally, there are no climate pledges or targets cascaded from a parent company, as Collegium Pharmaceutical operates independently in this regard. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction; however, Collegium Pharmaceutical has yet to publicly align with such initiatives.
How Carbon Intensive is Collegium Pharmaceutical, Inc.'s Industry?
How Carbon Intensive is Collegium Pharmaceutical, Inc.'s Location?
Collegium Pharmaceutical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Collegium Pharmaceutical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
